The GLP-1 Effect: How Weight-Loss Drugs Are Changing the Business of Healthcare

Key Concepts

• GLP-1 Agonists: A class of medications (e.g., Ozempic, Wegovy, Zepbound) originally for diabetes/weight management that have become a cultural and economic phenomenon.
• Pharmacy Benefit Managers (PBMs): Third-party administrators that manage prescription drug benefits, negotiate rebates with manufacturers, and dictate formulary placement.
• Formulary: The list of prescription drugs covered by a health insurance plan.
• Rebate-Driven Pricing: A model where manufacturers pay PBMs rebates to secure preferred status on a formulary, often leading to inflated list prices.
• Vertical Integration: The consolidation of PBMs, pharmacies, and clinical management services under single corporate entities, which can create conflicts of interest.

---

1. The Economic Impact of GLP-1s on Employer Health Plans

The rapid adoption of GLP-1 medications has created a significant financial strain on employer-sponsored healthcare.

• Market Penetration: Approximately 6% of members on employer health plans are currently utilizing these medications.
• Pharmacy Spend: GLP-1s now account for roughly 20% of total pharmacy expenditures for many employers.
• Sustainability Crisis: With treatment costs reaching approximately $10,000 per person annually, employers are struggling to balance these costs while maintaining coverage for other essential health services.

2. Structural Issues and Misconceptions

Paul Puit highlights that the current crisis is not just a health issue, but a systemic business problem driven by how drugs are priced and managed.

• Lack of Clinical Rigor: Many patients are using these drugs long-term without the intended lifestyle interventions or medical oversight, turning a "short-term crutch" into a permanent, expensive dependency.
• The Rebate Trap: A major misconception is that list prices reflect the true cost of drugs. In reality, manufacturers often inflate list prices to cover the rebates demanded by PBMs to secure "preferred" or "exclusive" status on insurance formularies.
• The "Veiled" System: PBMs operate behind the scenes, often prioritizing drugs that generate higher rebate revenue rather than those that are most cost-effective or clinically necessary for the patient.

3. Consequences for the Average Employee

The financial burden of GLP-1 coverage is not limited to those taking the drugs; it affects the entire workforce:

• Premium Increases: As employers face massive bills, they are forced to pass costs onto employees through higher premiums.
• Benefit Erosion: To offset costs, employers may increase deductibles, raise co-pays, or eliminate coverage for certain medications entirely.
• Access vs. Insurance: Puit notes that having insurance does not guarantee access; even with a high-level plan, a patient might face a $1,000 out-of-pocket cost before a deductible is satisfied.

4. Proposed Solutions and Market Shifts

Puit suggests that the current system requires structural reform rather than just increased spending.

• Direct-to-Consumer (DTC) Models: Manufacturers are increasingly offering cash-pay programs that bypass the insurance/PBM rebate system. These programs often provide a "fairer" price for individuals who do not have insurance coverage for these drugs.
• Addressing Vertical Integration: Puit identifies the consolidation of the healthcare ecosystem—where PBMs own the pharmacies and clinical management arms—as the primary target for reform. He argues that this integration creates revenue streams that are often misaligned with the actual needs of patients and employers.

5. Notable Quotes

• "It’s been very detrimental, very devastating and a lot of employers are looking at this saying, 'What are we supposed to do about it?'" — Paul Puit, regarding the impact of GLP-1s on pharmacy spend.
• "When you have rebates, the manufacturer has to raise their pricing to pay those rebates; if they didn't exist, the pricing could be much lower." — Paul Puit, explaining the inflationary effect of the rebate model.
• "One of the big challenges is vertical integration... there’s lots of ways for them to make revenue which doesn’t always equal alignment with what their clients or customers need." — Paul Puit, on the systemic issues within PBMs.

---

Synthesis/Conclusion

The rise of GLP-1 medications has exposed deep inefficiencies in the U.S. healthcare system. The current model, characterized by high list prices, rebate-driven PBM negotiations, and vertical integration, is proving unsustainable for employers. While direct-to-consumer pricing offers a temporary workaround for some, long-term stability will likely require structural changes to how PBMs operate and how drug prices are negotiated to ensure that clinical necessity—rather than rebate revenue—drives access to care.